Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window

Summary

This study is designed to evaluate the efficacy of IV rhTNK-tPA between 4.5 to 24 hours from symptom onset in patients presenting with a non-large vessel occlusion ischemic stroke.

Timeline

Start

2023-06-02

Primary completion

2025-10-28

Completion

2025-10-28

Publications

• Ma G, Mo R, Zuo Y, Ma Q, Zhao G, Yao X, Liang J, Zhou L, He Y, Long F, Yuan Z, Liu L, Han G, Tan Y, Ai Z, Cai C, Liu J, Zhang L, Yang H, Yi T, Li L, Fu Y, Zhang Y, Shao X, Yu Z, Wu S, Du Y, Mao L, Guo H, Chen X, Chen Y, Zhao Q, Chi L, Liu Y, Zhang H, Li G, Meng S, Wu Y, Wu J, Jiang Z, Lei S, Gao D, Zhong L, Fiehler J, Wang D, Nguyen TN, Saver JL, Hao J; OPTION Investigators. Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial. JAMA. 2026 Apr 7;335(13):1137-1147. doi: 10.1001/jama.2026.0210.

Drugs

Indications